|
|
||||||||
1Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, Vermont; 2Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island; 3Department of Cell Biology, University of Calabria, Cosenza, Italy; and 4Department of Obstetrics and Gynecology, Karolinska Institutet, Clintec, Karolinska University Hospital-Huddinge, Stockholm, Sweden
Submitted 8 August 2007 ; accepted in final form 10 January 2008
The objectives of this study were to determine whether placental growth factor (PlGF) exerts a vasodilatory effect on rat uterine vessels (arcuate arteries and veins) and to examine regional differences in reactivity by comparing these responses to those of comparably sized mesenteric vessels. We also sought to examine and compare its effects on human uterine and subcutaneous vessels. All vessels were studied in vitro, under pressurized (rat) or isometric wire-mounted (human) conditions, and exposed to a range of PlGF concentrations. Inhibitors of nitric oxide and prostaglandin synthesis were included in an effort to understand the causal mechanism(s). In rat uterine arteries, the effects of receptor inhibition and activation using selective ligands for VEGFR-1 (PlGF) vs. VEGFR-2 (VEGF-E) were determined, and real-time RT-PCR was performed to evaluate the effect of pregnancy on relative abundance of VEGFR-1 and VEGFR-2 message in the vascular wall. PlGF was a potent vasodilator of all vessels studied, with greatest sensitivity observed in rat uterine arteries. Pregnancy significantly augmented dilator sensitivity to PlGF, and this effect was associated with selective upregulation of VEGFR-1 message in the pregnant state. The contribution of nitric oxide was appreciable in rat and human uterine arteries, with lesser effects in rat uterine veins and mesenteric arteries, and with no observable effect in human subcutaneous vessels. Based on these results, we conclude that PlGF is a potent vasodilator of several vessel types in both humans and rats. Its potency and mechanism vary with physiological state and vessel location and are mediated solely by the VEGFR-1 receptor subtype. Gestational changes in the uterine circulation suggest that this factor may play a role in modulating uterine vascular remodeling and blood flow during the pregnant state.
vascular endothelial growth factor; nitric oxide; uterine circulation; rat; human resistance arteries; vascular endothelial growth factor receptor-1; fms-like tyrosine kinase-1
This article has been cited by other articles:
![]() |
H. Suzuki, A. Ohkuchi, S. Matsubara, Y. Takei, M. Murakami, M. Shibuya, M. Suzuki, and Y. Sato Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice Hypertension, November 1, 2009; 54(5): 1129 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fuller, C. Barron, M. Mandala, N. Gokina, and G. Osol Predominance of Local Over Systemic Factors in Uterine Arterial Remodeling During Pregnancy Reproductive Sciences, May 1, 2009; 16(5): 489 - 500. [Abstract] [PDF] |
||||
![]() |
R. B. Gombos, V. Wolan, K. McDonald, and D. G. Hemmings Impaired vascular function in mice with an active cytomegalovirus infection Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H937 - H945. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |